Hemovigilance in Germany - Reports to the Paul-Ehrlich-Institut between January 1995 and December 2002 concerning suspected transfusion reactions;Hämovigilanz in Deutschland - Berichte an das Paul-Ehrlich-Institut über verdachtsfälle von transfusions-reaktionen im beobachtungszeitraum Januar 1995 bis Dezember 2002

Transfusion Medicine and Hemotherapy

Volumn 30, Issue 5, 2003, Pages 232-238

  Graul, A ^a   Heiden, M ^a   Graf K ^a   Keller Stanislawski, B ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Bacterial contamination; Hemovigilance; Look back procedure; TRALI; Transfusion reaction; Virus transmission

Indexed keywords

INFUSION FLUID;

ALLERGIC REACTION; ARTICLE; BACTERIUM CONTAMINATION; BLOOD DONOR; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD TRANSFUSION REACTION; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGICAL MONITORING; LETHALITY; LUNG INJURY; NUCLEIC ACID AMPLIFICATION; SCREENING TEST; VIRUS DETECTION; VIRUS TRANSMISSION;

EID: 0345017202     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000074289     Document Type: Article

References (19)

1. Andreu G, Morel P, Forestier F, Debeir J, Rebibo D, Janvier G, Herv́ PL: Hemeovigilance network in France: Organisation and analysis of immediate transfusion incident reports from 1994 to 1998. Transfusion 2002;42:1356-1364.
2. McClelland B, Love E, Scott S, Williamson LM: Haemovigilance. Concept, Europe UK Initiatives. Vox Sang 1998;74(suppl 2):431-439.
3. Menitove JE: Hemovigilance in the United States of America. Vox Sang 1998;74(suppl 2):447-455.
4. Bekanntmachung des Bundesinstituts für Arzneimittel und Medizinprodukte und des Paul-Ehrlich-Instituts zur Anzeige von Nebenwirkungen, Wechselwirkungen und Arzneimittelmissbrauch nach § 29 Abs. 1 Satz 2 bis 8 AMG. Bundesanzeiger Nr. 97 vom 25. Mai 1996, S. 5929.
5. Graul A, Keller-Stanislawski B: Hämovigilanz von Blutkomponenten. Meldungen an das Paul-Ehrlich-Institut vom 1.1.1995 bis zum 15.11.1998. Bundesgesundheitsbl Gesundheitsforschung Gesundheitsschutz 1999;42:143-149.
6. Humpe A, Heermann KH, Koehler M: Infektion mit Hepatitis-C-Virus durch Quarantäneplasma: Dtsch Ärztebl 1999;96:C2014-C2018.
7. Dreier J, Götting C, Wolff C, Petersen N, Kleesiek K: Recent experience with human immunodeficiency virus transmission by cellular blood products in Germany: Antibody screening is not sufficient to prevent transmission. Vox Sang 2002;82:80-83.
8. Glück D, Kubanek B, Maurer C, Petersen N: Seroconversion of HIV, HCV, and HBV in blood donors in 1996 - Risk of virus transmission by blood products in Germany. Infusionsther Transfusionsmed 1998;25:82-84.
9. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. N Engl J Med 1996;334:1685-1690.
10. Schüttler CG, Caspari G, Jursch CA, Willems WR, Gerlich WH, Schaefer S: Hepatitis C virus transmission by a blood donation negative in nucleic acid amplification tests for viral RNA: Lancet 2000; 355:41-42.
11. Glück D: Risiko der HIV-, HCV- und HBV-Übertragung durch Blutpräparate. Infusionsther Transfusionsmed 1999;26:335-338.
12. Caspari G, Gerlich W, Jilg W: Bluttransfusionen und Hepatitis B: ein altes Problem im neuen Gewand: Dtsch Ärztebl 1995;92;A-2116-2118.
13. Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP: Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: Implications for transfusion and donor screening. Transfusion 2003;43:696-704.
14. Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Günther S, Hess G, Hüdig H, Kitchen A, Margolis H, Michel G, Trepo C, Will H, Zanetti A, Mushahwar I: Serological pattern 'anti-HBc alone': Report on a Workshop. J Med Virol 2000;62:450-455.
15. Allain JP, Reeves I, Kitchen AD, Wenham D, Williamson LM: Feasibility and usefulness of an efficient anti-HBc screening program in blood donors. Transfus Med 1995;5:259-265.
16. Petersen LR, Satten GA, Dodd R, Busch M, Kleinman S, Grindon A, Lenes B: Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group. Transfusion 1994;34:283-289.
17. Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, Read S, Dodd RY, Petersen LRL: Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: Implications for screening of blood and tissue donors. Transfusion 1995;35:91-97.
18. Höher PG: Mikrobielle Sicherheit von Blutproduk-ten. Infusionsther Transfusionsmed 1996;23:42-58.
19. Noel L, Debeir J, Cosson A: The French haemovigilance system. Vox Sang 1998;74:441-445.